Amgen’s BLINCYTO sBLA to be assessed by FDA for treating MRD
Amgen asserted that the Oncologic Drugs Advisory Committee of the U.S Food and Drug Administration will assess the data supporting the BLINCYTO supplemental Biologics License…
Read More...
Read More...
